First registered RCT of BPC-157: SubQ vs placebo for acute hamstring strain (NCT07437547)
Provenance: registered interventional RCT (recruiting — no results yet)
ClinicalTrials.gov record NCT07437547. Page is JS-rendered; details below are from the search-engine record and corroborated by a 2026 peer-reviewed narrative review. This is the first properly registered randomized, placebo-controlled trial of BPC-157 for a musculoskeletal indication — a meaningful credibility step, but it is recruiting, not reported.
Key findings
- NCT07437547 — randomized, placebo-controlled trial: subcutaneous BPC 157 once daily for 14 days vs matching placebo in adults with acute hamstring muscle strain, with tissue-repair endpoints.
- Context (peer-reviewed): the 2026 narrative review “Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing” (PMC12446177) confirms human evidence remains 3 small uncontrolled pilot studies (interstitial cystitis; IV safety/PK; retrospective intra-articular knee) — this RCT is the first controlled human test.
Why it matters for this base
- BPC-157 is a flagship healing product whose #1 weakness is human evidence (animal-only since ~1993; the KB note flags only “3 tiny studies” and a “US phase-2 hamstring trial reportedly underway”). This upgrades that anecdote to a registered RCT and is exactly the kind of data a serious customer asks for.
- If it reads out positive, this becomes P0 news for the Healing & Recovery cluster.
Caveats
- Recruiting / registered only — no results. Registration ≠ efficacy or safety conclusion. BPC-157 remains not FDA-approved; research/educational use only. Tumor-growth caution (VEGF upregulation) unchanged.
Corroborating sources
- ClinicalTrials.gov NCT07437547; Regeneration or Risk? narrative review (PMC12446177, 2026); Peptide Database / Peptide Catalog human-trial status trackers (2026).